Palexia 75 mg film-coated tablets

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

PALEXIA 75 mg film-coated tablets

Tapentadol

Read the entire leaflet carefully before you start taking this medicine, because it contains

important information for you.

• Keep this leaflet, as you may need to read it again.

• If you have any questions, ask your doctor or pharmacist.

• This medicine has been prescribed for you only, and you should not give it to others, even if they have the same symptoms as you, because it could harm them.

• If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Leaflet contents

1. What PALEXIA 75 mg is and what it is used for

2. What you need to know before taking PALEXIA 75 mg

3. How to take PALEXIA 75 mg

4. Possible side effects

   1. Storage of PALEXIA 75 mg

5. Contents of the pack and other information

1. What PALEXIA 75 mg is and what it is used for

Tapentadol—the active substance in PALEXIA—is a pain medication belonging to the class of strong opioids. PALEXIA 75 mg is used for the treatment of moderate to severe acute pain in adults, which can only be adequately managed with an opioid.

2. What you need to know before starting to take PALEXIA 75 mg

Do not take PALEXIA 75 mg:

• if you are allergic to tapentadol or to any of the other ingredients of this medicine (listed in section 6),
• if you have asthma or if your breathing is slow or shallow to dangerous levels [respiratory depression; hypercapnia (higher than normal concentration of carbon dioxide in the blood)],
• if you have a condition in which the intestine does not function properly (intestinal paralysis),
• if you have consumed alcohol, sleeping pills, other painkillers, or other psychotropic medicines (medicines that affect mood and emotions) in high doses (see section "Taking PALEXIA 75 mg with other medicines").

Warnings and precautions

Consult your doctor or pharmacist before starting to take PALEXIA 75 mg:

• if your breathing is slow or shallow,
• if you have increased intracranial pressure or altered consciousness up to and including coma,
• if you have sustained a head injury or have brain tumors,
• if you have liver or kidney disease (see section “How to take PALEXIA 75 mg”),
• if you have a disease of the pancreas (such as pancreatitis) or of the biliary tract,
• if you are taking medicines known as mixed opioid agonist/antagonists (e.g.: pentazocine, nalbuphine) or partial µ-opioid receptor agonists (e.g.: buprenorphine),
• if you are prone to epilepsy or seizures, or if you are taking other medicines known to carry a risk of increasing seizures, as the risk of such seizures may increase.

Tolerance, dependence, and addiction

This medicine contains tapentadol, which is an opioid medicine. Repeated use of opioids may reduce the effectiveness of the medicine (you may become accustomed to it, which is known as tolerance). Repeated use of PALEXIA 75 mg may also lead to dependence, abuse, and addiction, which can result in potentially fatal overdose. The risk of adverse effects may increase with higher doses and longer duration of use.

Dependence or addiction may make you feel that you no longer have control over how much medicine you need to take or how often you need to take it. The risk of becoming dependent or addicted varies from person to person. You may have a higher risk of becoming dependent or addicted to PALEXIA 75 mg if:

• you or a family member has a history of alcohol, prescription medicine, or illicit substance abuse or dependence (“addiction”),
• you are a smoker,
• you have ever had problems with your mood (depression, anxiety, or a personality disorder) or have received treatment from a psychiatrist for other mental illnesses.

If you notice any of the following signs while taking PALEXIA 75 mg, it could be a sign that you have become dependent or addicted:

• you need to take the medicine for longer than recommended by your doctor,
• you need to take higher doses than recommended,
• you may feel that you need to keep taking the medicine even when it is not helping to relieve pain,
• you are using the medicine for reasons other than prescribed, for example, “to calm down” or “to help you sleep”,
• you have made repeated unsuccessful attempts to stop or control the use of the medicine,
• you feel unwell when you stop taking the medicine and feel better when you start taking it again (“withdrawal symptoms”).

If you notice any of these signs, speak with your doctor to discuss the most appropriate treatment strategy for your case, including when it is appropriate to stop taking the medicine and how to do so safely (see section 3 “If you stop treatment with PALEXIA 75 mg”).

Sleep-related breathing disorders

PALEXIA 75 mg may cause sleep-related breathing disorders such as sleep apnea (pauses in breathing during sleep) and sleep-related hypoxemia (low levels of oxygen in the blood). Symptoms may include pauses in breathing during sleep, nighttime awakenings due to difficulty breathing, difficulty maintaining sleep, or excessive daytime sleepiness. If you or someone else notices these symptoms, consult your doctor. Your doctor may consider reducing the dose.

Taking PALEXIA 75 mg with other medicines

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicine.

The risk of side effects increases if you are taking medicines that may cause seizures (fits), such as certain antidepressants or antipsychotics. The risk of seizures increases if you take PALEXIA 75 mg at the same time as these medicines. Your doctor will tell you whether PALEXIA 75 mg is suitable for you.

Concomitant use of PALEXIA 75 mg and sedative medicines such as benzodiazepines or related medicines (certain sleeping tablets or tranquilizers [e.g., barbiturates] or analgesics such as opioids, morphine, and codeine [also as a cough medicine]), antipsychotics, H1 antihistamines, or alcohol increases the risk of drowsiness, breathing difficulties (respiratory depression), coma, and may be potentially fatal. Because of this, concomitant use should only be considered when no other treatment options are possible.

However, if your doctor prescribes PALEXIA 75 mg with sedative medicines, your dose and duration of concomitant treatment should be limited.

Concomitant use of opioids and medicines used to treat epilepsy, nerve pain, or anxiety (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression, and may be potentially fatal.

Inform your doctor if you are taking gabapentin or pregabalin or any other sedative medicine, and strictly follow your doctor’s dosage recommendations. It may be helpful to inform your friends and family about the signs and symptoms listed above. Inform your doctor if you experience any of these symptoms.

If you are taking a type of medicine that affects serotonin levels (e.g., certain medicines to treat depression), talk to your doctor before taking PALEXIA 75 mg, as cases of "serotonin syndrome" have been reported. Serotonin syndrome is a rare but potentially life-threatening condition. Symptoms may include rhythmic involuntary muscle contractions, including muscles controlling eye movement, agitation, excessive sweating, tremors, exaggerated reflexes, increased muscle tension, and body temperature above 38°C. Your doctor can provide further information.

The co-administration of PALEXIA 75 mg with other types of medicines known as mixed opioid µ-receptor agonist/antagonists (e.g., pentazocine, nalbuphine) or partial µ-opioid agonists (e.g., buprenorphine) has not been studied. PALEXIA 75 mg may not have the same effectiveness if administered together with one of these medicines. Inform your doctor if you are currently being treated with any of these medicines.

Administration of PALEXIA 75 mg together with strong inhibitors or inducers (e.g., rifampicin, phenobarbital, St. John’s wort) of certain enzymes required to eliminate tapentadol from your body may affect the efficacy of tapentadol or may cause adverse effects, especially when starting or stopping this other medication. Keep your doctor informed about all medicines you are taking.

PALEXIA 75 mg must not be taken together with MAO inhibitors (medicines used to treat depression). Inform your doctor if you are taking MAO inhibitors or have taken them within the last 14 days.

If you use PALEXIA 75 mg together with the following medicines that have anticholinergic effects, the risk of side effects may increase:

• medicines to treat depression,
• medicines used to treat allergies, dizziness, or nausea (antihistamines or antiemetics),
• medicines to treat psychiatric disorders (antipsychotics or neuroleptics),
• muscle relaxants,
• medicines to treat Parkinson’s disease.

Taking PALEXIA 75 mg with food, drinks, and alcohol

Do not consume alcohol while taking PALEXIA 75 mg, as this may increase some of its adverse effects, such as drowsiness. Taking food does not affect the action of this medicine.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medicine.

Do not take this medicine:

• if you are pregnant, unless your doctor has instructed you to do so; if used for prolonged periods during pregnancy, tapentadol may cause withdrawal symptoms in the newborn, which can be life-threatening if not detected and treated by a doctor,
• during childbirth, as it may cause slow or shallow breathing up to dangerous levels (respiratory depression) in the newborn,
• during breastfeeding, as it may be excreted in breast milk.

Driving and using machines

Ask your doctor whether you can drive or use machines during treatment with PALEXIA. It is important to observe how this medicine affects you before driving or operating machinery. Do not drive or use machines if you feel drowsy, dizzy, have blurred vision, or have difficulty concentrating. Take special care at the beginning of treatment, after a dose change, and when taking it together with alcohol or tranquilizers.

PALEXIA 75 mg contains lactose

If your doctor has informed you that you have an intolerance to certain sugars, consult with them before taking this medicine.

PALEXIA 75 mg contains sodium

This medicine contains less than 1 mmol (23 mg) of sodium per tablet and is therefore considered essentially “sodium-free.”

3. How to take PALEXIA 75 mg

Follow exactly the instructions for administration of this medicine as given by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.

Before starting treatment and periodically during treatment, your doctor will discuss with you what to expect from using PALEXIA 75 mg, when and for how long you should take it, when to contact your doctor, and when you should stop taking it (see also “If you stop taking PALEXIA 75 mg”).

Your doctor will adjust the dose according to the intensity of your pain and your individual sensitivity to pain. Generally, the lowest effective dose required to relieve pain should be used.

Adults

The usual starting dose is 50 mg every 4 to 6 hours.

Your doctor may prescribe a different or more suitable dosage regimen if necessary. If you think the effect of these tablets is too strong or too weak, consult your doctor or pharmacist.

Total daily doses exceeding 700 mg of tapentadol are not recommended during the first day of treatment, nor are total daily doses exceeding 600 mg of tapentadol recommended on subsequent treatment days.

Elderly patients

In elderly patients (over 65 years of age), dose adjustment is usually not necessary. However, elimination of tapentadol may be delayed and slower in certain patients in this age group. If this applies to you, your doctor may prescribe a different dosage regimen.

Liver and kidney disease (hepatic and renal impairment)

Patients with severe liver problems must not take these tablets. If you have moderate liver problems, your doctor will prescribe a different dosage regimen. Dose adjustment is not necessary in cases of mild liver problems.

Patients with severe kidney problems must not take these tablets. Dose adjustment is not necessary in cases of mild or moderate kidney problems.

Use in children and adolescents

PALEXIA 75 mg is not indicated for use in children and adolescents under 18 years of age.

How and when to take PALEXIA 75 mg

PALEXIA 75 mg should be taken orally.

Take the tablets with sufficient liquid. You may take them on an empty stomach or with food.

How long to take PALEXIA 75 mg

Do not take the tablets for longer than your doctor has prescribed.

If you take more PALEXIA 75 mg than you should

After taking very high doses, you may experience one or more of the following effects:

• markedly constricted pupils, vomiting, low blood pressure, rapid heartbeat, fainting, altered consciousness or coma (deep loss of consciousness), epileptic seizures, dangerously slow or shallow breathing, or respiratory arrest, which may lead to death.

If any of these occur, call a doctor immediately!

In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately or call the Toxicology Information Service at telephone number: 91 562 04 20, indicating the medicine and the amount taken. It is recommended to bring the medicine packaging and leaflet to the healthcare professional.

If you forget to take PALEXIA 75 mg

If you forget to take a tablet, you may experience a return of pain. Do not take a double dose to make up for missed doses; instead, continue taking the tablets as before.

If you stop taking PALEXIA 75 mg

If you stop or discontinue treatment too early, you may experience a return of pain. If you wish to stop treatment, consult your doctor before doing so.

Generally, patients do not experience any adverse effects after stopping treatment, but in rare cases, individuals who have taken the tablets for a prolonged period may feel unwell if they stop taking them suddenly.

Symptoms may include:

• restlessness, watery eyes, runny nose, yawning, sweating, chills, muscle pain, and dilated pupils,
• irritability, anxiety, back pain, joint pain, weakness, abdominal cramps, difficulty sleeping, nausea, loss of appetite, vomiting, diarrhea, and increases in blood pressure, respiratory rate, or heart rate.

If you experience any of these symptoms after stopping treatment, consult your doctor.

You must not stop taking this medicine abruptly, unless your doctor specifically instructs you to do so. If your doctor wants you to stop taking these tablets, they will advise you on how to do so, which may involve gradually reducing the dose.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

Important adverse effects or symptoms to watch for, and what to do if you experience them:

This medicine may cause allergic reactions. Symptoms may include wheezing (a whistling sound when breathing), difficulty breathing, swelling of the eyelids, face or lips, skin rash or itching, especially if affecting the entire body.

Another serious adverse effect is abnormally slow or weak breathing. This occurs mostly in elderly or debilitated patients.

If you experience any of these serious symptoms, consult your doctor immediately.

Adverse effects that may occur:

Very common (may affect more than 1 in 10 people): nausea, vomiting, dizziness, drowsiness, headache.

Common (may affect up to 1 in 10 people): loss of appetite, anxiety, confusion, hallucinations, difficulty sleeping, sleep disturbances, tremors, hot flushes, constipation, diarrhoea, indigestion, dry mouth, itching, increased sweating, skin rashes, muscle cramps, feeling weak, tiredness, sensation of change in body temperature.

Uncommon (may affect up to 1 in 100 people): low mood, disorientation, excitability (agitation), nervousness, restlessness, euphoric mood, drug dependence, attention disturbances, memory impairment, feeling faint, sedation, difficulty controlling movements, difficulty speaking, numbness, abnormal sensations in the skin (e.g. tingling, itching), muscle tics, visual disturbances, rapid heartbeat, palpitations, decreased blood pressure, slow or shallow breathing up to dangerous levels (respiratory depression), reduced oxygen levels in the blood, shortness of breath, abdominal discomfort, rash, feeling of heaviness, delayed urination, frequent urination, drug withdrawal syndrome (see section “If you stop taking PALEXIA 75 mg”), fluid accumulation in tissues (oedema), malaise, feeling of drunkenness, irritability, sensation of relaxation.

Rare (may affect up to 1 in 1,000 people): allergic reaction to medicines (including swelling under the skin, urticarial rash, and in severe cases difficulty breathing, low blood pressure, collapse or shock), disturbance in thinking, epileptic seizures, decreased level of consciousness, impaired coordination, slow heartbeat, delayed gastric emptying.

Frequency not known (frequency cannot be estimated from available data): delirium.

In general, the risk of suicidal thoughts and behaviour increases in patients with chronic pain. In addition, some medicines used to treat depression (which affect the brain’s neurotransmitter system) may increase this risk, especially at the beginning of treatment. Although tapentadol also affects neurotransmitters, experience in patients has not shown that it increases this risk.

Reporting of adverse effects

If you experience any adverse effect, talk to your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You may also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of PALEXIA 75 mg

Keep this medicine out of the sight and reach of children.

Store this medicine in a safe and secure place, where others cannot access it. It may cause serious harm or be fatal to individuals who take it accidentally or intentionally when it has not been prescribed for them.

Do not use this medicine after the expiry date stated on the carton and blister pack. The expiry date refers to the last day of the month indicated.

This medicine does not require any special storage conditions.

Medicines must not be disposed of via wastewater or household waste. Dispose of empty containers and unused medicines at a SIGRE Point at your pharmacy. If you have any doubts, ask your pharmacist how to properly dispose of containers and medicines you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of PALEXIA 75 mg

The active substance is tapentadol.

Each tablet contains 75 mg of tapentadol (as 87.36 mg of tapentadol hydrochloride).

The other components are:

Tablet core: microcrystalline cellulose, lactose monohydrate, sodium croscarmellose, povidone K30, magnesium stearate.
Tablet film-coating: polyvinyl alcohol, titanium dioxide (E 171), macrogol 3350, talc, yellow iron oxide (E 172), red iron oxide (E 172).

Appearance of the product and contents of the pack

Film-coated tablets, round, light yellow in colour, 8 mm in diameter, with the Grünenthal logo engraved on one side and “H7” on the other.

PALEXIA film-coated tablets are packaged in blisters and supplied in pack sizes of 5, 10, 10x1, 14, 14x1, 20, 20x1, 24, 28, 28x1, 30, 30x1, 40, 50, 50x1, 54, 56, 56x1, 60, 60x1, 90, 90x1, 100 and 100x1 tablets.

Not all pack sizes may be marketed.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder:

Grünenthal Pharma, S.A.
Doctor Zamenhof, 36 – 28027 Madrid, Spain

Manufacturer:

Grünenthal GmbH
Zieglerstrasse, 6 – D-52078 Aachen, Germany

This medicinal product is authorized in the European Economic Area countries and in the United Kingdom (Northern Ireland) under the following names:

Germany: Palexia Akutschmerz

Austria, Belgium, Cyprus, Croatia, Denmark, Slovenia, Spain, Greece, Netherlands, Ireland, Italy, Luxembourg, Norway, Poland, Portugal, United Kingdom (Northern Ireland), Czech Republic, Slovak Republic, Sweden: PALEXIA

Date of the most recent revision of this leaflet: January 2026

Detailed and up-to-date information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/